Breaking Finance News

Galapagos NV GLPG (NYSE:GLPG) has been upgraded from Sell to Neutral in a report by Janney Capital today.

Just yesterday Galapagos NV GLPG (NYSE:GLPG) traded 3.29% higher at $76.88. Galapagos NV GLPG’s 50-day moving average is $0.00 and its 200-day moving average is $0.00. The last closing price is up 0.00% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.05% over the same time period. 353,470 shares of Galapagos NV GLPG exchanged hands, up from an avg. volume of 0

Janney Capital has upgraded Galapagos NV GLPG (NYSE:GLPG) from Sell to Neutral in a report released on 7/07/2017.

Previously on 6/20/2017, BTIG Research reported on Galapagos NV GLPG (NYSE:GLPG) increased the target price from $0.00 to $98.00. At the time, this indicated a possible upside of 0.24%.

Performance Chart

Galapagos NV GLPG (NYSE:GLPG)

With a total market value of $0, Galapagos NV GLPG has with a one year low of $52.50 and a one year high of $94.88 .

A total of 1 equity analyst has released a ratings update on GLPG. zero equity analysts rating the company a strong buy, two equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $92.78.

Brief Synopsis About Galapagos NV GLPG (NYSE:GLPG)

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *